# Veracyte share price today (Veracyte, Inc., VCYT)

> Veracyte, Inc.'s results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 22% of past readings. VCYT · Healthcare · Diagnostics & Research · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/vcyt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $50.29 (+39.4% in a year)
- P/E: 36.1× (lower than 78% of the last 1 year)
- Revenue (Jun 2026): $150 M (+15.5% on a year ago)
- Profit (Jun 2026): $25.5 M
- Operating margin: 15.3% (+3.6 points on a year ago)
- ROE: 5%, FY25
- ROIC: 9.7%, against a 14.8% cost of capital: −5.1 points
- Profit that came in as cash: 234%, last 2 years

The main question: yearly earnings per share moved +164.5% while the share price moved +39.4%. ## What is the Veracyte share price today? Veracyte, Inc.'s share price was $50.29 at the close on 3 November 2026. It has been rising for 7 weeks. That is 17.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $30 and $60, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 10 years the share price moved +908% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Veracyte pay? Veracyte, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Veracyte on? Veracyte is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Veracyte profitable? Veracyte, Inc. earned $25.5 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $66.4 M. That is 17.0% of the quarter's revenue. The same quarter a year earlier lost $980 K. 4 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $66.4 M (+174.9% on the year before). On average over the last four quarters, profit changed +346.2% and revenue +17.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Veracyte make, and is it growing? Veracyte, Inc. reported $150 M of revenue in the Jun 2026 quarter, +15.5% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 23.9% a year on average. The last full year, FY25, came in at $517 M. The last four reported quarters add to $562 M. FY25 revenue was $517 M, +16.0% on the year before. Recent pace: the last four quarters grew +17.3% on average, against 23.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +17.3%, against +18.6% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Veracyte keep? Veracyte, Inc.'s operating margin was 15.3% in the Jun 2026 quarter, 3.6 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −36.9% and 12.2%. The latest quarter is above every full year in that period. Across 5 years it has been between −36.9% and 12.2%, and FY25's 12.2% is the highest of them. Why the margin moved: operating margin changed +3.6 percentage points on the year while gross margin changed +2.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Veracyte's profit turning into cash? Over the last 2 years, 234% of Veracyte, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $136 M of operating cash against $66.4 M of profit. After $9.7 M of spending on assets, $127 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Veracyte's cash go? Veracyte, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $30.9 M on assets over the last 3 years. Averaged over those years that is 2.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $30.9 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Veracyte's P/E ratio, and how does it compare with its own history? Veracyte, Inc.'s P/E is 36.1×, near the low end of its own history: it has been lower only 22% of the time. Its usual P/E (the middle reading) is 66.1×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +164.5% while the price moved +39.4%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Veracyte business getting better or worse? Veracyte, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Veracyte earn on its capital? Veracyte, Inc. earned a ROE of 5% in FY25. That is up from a low of −7% in FY23. Its return on capital used (ROIC) is 5.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 12.8% net margin and 0.37× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 12.8% net margin × 0.37× asset turnover × 1.07× leverage (assets divided by equity) ≈ 5.1% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 9.7% − 14.8% = −5.1 percentage points. The 14.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 9.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 6.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Veracyte have too much debt? Veracyte, Inc. has total debt of $40.1 M against shareholder equity of $1.4 B as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.03 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Veracyte shareholding pattern? 12.3% of Veracyte, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Veracyte from balance-sheet trouble? For Veracyte, Inc., the Z-score is 18.60. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 18.60 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Veracyte rank in its industry? 47.5 out of 100, rank 20 of 30 in Diagnostics & Research, with 64% of the evidence available. Veracyte, Inc. scores 47.5 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 20. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 22.3 + 10.8 + 9 + 5.4 = 47.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Veracyte compared with? Veracyte ranks 20 of 30 Diagnostics & Research companies on the 4-Factor Sector Score, with 47.5 out of 100. 1. [CareDx, Inc.](https://www.sectoralpha.in/us/stocks/cdna) CDNA · leader · Evidence leans up · 64% evidence 62.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 33.9% · Profit 93.1% · Operating margin change 12.6 points · 62% evidence Capital efficiency 7.2/25 · ROCE -0.4% · Operating margin 0.2% · 76% evidence Valuation 10.6/20 · P/E 13.3× · PEG n/a · 15% evidence Relative strength 19.9/20 · Lead over its industry 110.8% · Lead over S&P 500 166.5% · 1 year 466.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.1 + 7.2 + 10.6 + 19.9 = 62.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Agilent Technologies, Inc.](https://www.sectoralpha.in/us/stocks/a) A · leader · Evidence leans up · 85% evidence 62.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 8.6% · Profit 18% · Operating margin change 2.9 points · 95% evidence Capital efficiency 18.4/25 · ROCE 15.4% · Operating margin 25.6% · 76% evidence Valuation 11.1/20 · P/E 27.1× · PEG 1.41 · 65% evidence Relative strength 11.7/20 · Lead over its industry -8.9% · Lead over S&P 500 21.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.8 + 18.4 + 11.1 + 11.7 = 62 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Medpace Holdings, Inc.](https://www.sectoralpha.in/us/stocks/medp) MEDP · leader · Evidence leans up · 85% evidence 61.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 20.3% · Profit 19.4% · Operating margin change 1.6 points · 95% evidence Capital efficiency 21.3/25 · ROCE 75.3% · Operating margin 23.1% · 76% evidence Valuation 12.2/20 · P/E 33.6× · PEG 1.29 · 65% evidence Relative strength 8.7/20 · Lead over its industry -11.9% · Lead over S&P 500 17.3% · 1 year 12.6% · 100% evidence · 11 of 12 weeks ahead Exact sum: 19.1 + 21.3 + 12.2 + 8.7 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Revvity, Inc.](https://www.sectoralpha.in/us/stocks/rvty) RVTY · leader · Too little evidence to rank firmly · 58% evidence 60.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue n/a · Profit n/a · Operating margin change 3.3 points · 45% evidence Capital efficiency 12.8/25 · ROCE 4.3% · Operating margin 17.1% · 76% evidence Valuation 8.8/20 · P/E 53.4× · PEG n/a · 15% evidence Relative strength 18.2/20 · Lead over its industry 7% · Lead over S&P 500 41.6% · 1 year 80.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 12.8 + 8.8 + 18.2 = 60.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [IDEXX Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/idxx) IDXX · turning · Evidence leans up · 81% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/35 · Revenue 12.8% · Profit 15.5% · Operating margin change 1.4 points · 83% evidence Capital efficiency 21.3/25 · ROCE 68.1% · Operating margin 35% · 76% evidence Valuation 7.1/20 · P/E 36.4× · PEG 1.97 · 65% evidence Relative strength 8.0/20 · Lead over its industry -21.5% · Lead over S&P 500 6.4% · 1 year -5.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.1 + 21.3 + 7.1 + 8 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Labcorp Holdings Inc.](https://www.sectoralpha.in/us/stocks/lh) LH · leader · Evidence leans up · 81% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.3/35 · Revenue 6.4% · Profit 31.2% · Operating margin change 0.9 points · 83% evidence Capital efficiency 13.4/25 · ROCE 9.9% · Operating margin 12.2% · 76% evidence Valuation 15.2/20 · P/E 22.9× · PEG 0.69 · 65% evidence Relative strength 8.9/20 · Lead over its industry -11.1% · Lead over S&P 500 19.1% · 1 year 40% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.3 + 13.4 + 15.2 + 8.9 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [GRAIL, Inc.](https://www.sectoralpha.in/us/stocks/gral) GRAL · leader · Evidence leans up · 61% evidence 56.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 23% · Profit n/a · Operating margin change 36.1 points · 62% evidence Capital efficiency 3.9/25 · ROCE -19.3% · Operating margin -332% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 19.4/20 · Lead over its industry 25.5% · Lead over S&P 500 63.9% · 1 year 75.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.9 + 3.9 + 10 + 19.4 = 56.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Mettler-Toledo International Inc.](https://www.sectoralpha.in/us/stocks/mtd) MTD · leader · Evidence leans up · 81% evidence 55.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.0/35 · Revenue 6.9% · Profit 9% · Operating margin change 3.8 points · 83% evidence Capital efficiency 21.0/25 · ROCE 47.8% · Operating margin 31.2% · 76% evidence Valuation 6.8/20 · P/E 28.5× · PEG 2.27 · 65% evidence Relative strength 11.1/20 · Lead over its industry -11% · Lead over S&P 500 19.2% · 1 year 18% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17 + 21 + 6.8 + 11.1 = 55.9 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 9. [Natera, Inc.](https://www.sectoralpha.in/us/stocks/ntra) NTRA · leader · Evidence leans up · 64% evidence 54.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 37.8% · Profit n/a · Operating margin change 9.9 points · 62% evidence Capital efficiency 5.3/25 · ROCE -13.5% · Operating margin -10.3% · 76% evidence Valuation 11.4/20 · P/E -152.2× · PEG n/a · 15% evidence Relative strength 13.7/20 · Lead over its industry 9% · Lead over S&P 500 42.8% · 1 year 94.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 5.3 + 11.4 + 13.7 = 54.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Charles River Laboratories International, Inc.](https://www.sectoralpha.in/us/stocks/crl) CRL · leader · Evidence leans up · 64% evidence 53.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.6/35 · Revenue -0.7% · Profit n/a · Operating margin change -1.6 points · 62% evidence Capital efficiency 12.0/25 · ROCE 7.9% · Operating margin 15.1% · 76% evidence Valuation 11.3/20 · P/E -87.6× · PEG n/a · 15% evidence Relative strength 18.1/20 · Lead over its industry 17.8% · Lead over S&P 500 54.6% · 1 year 109.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11.6 + 12 + 11.3 + 18.1 = 53 · What this means: Relative strength against the index is 54.6%, and revenue and profit growth are weak. 11. [Quest Diagnostics Incorporated](https://www.sectoralpha.in/us/stocks/dgx) DGX · leader · Evidence leans up · 85% evidence 52.7 out of 100 Growth Capital Valuation Relative
12. [Adaptive Biotechnologies Corporation](https://www.sectoralpha.in/us/stocks/adpt) ADPT · leader · Evidence leans up · 64% evidence 52.1 out of 100 Growth Capital Valuation Relative
13. [Sotera Health Company](https://www.sectoralpha.in/us/stocks/shc) SHC · quiet · Evidence leans up · 71% evidence 51.3 out of 100 Growth Capital Valuation Relative
14. [IQVIA Holdings Inc.](https://www.sectoralpha.in/us/stocks/iqv) IQV · leader · Evidence leans up · 81% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [BillionToOne, Inc.](https://www.sectoralpha.in/us/stocks/blln) BLLN · turning · Too little evidence to rank firmly · 58% evidence 49.0 out of 100 Growth Capital Valuation Relative
16. [Danaher Corporation](https://www.sectoralpha.in/us/stocks/dhr) DHR · breaking out · Evidence leans down · 85% evidence 48.6 out of 100 Growth Capital Valuation Relative
17. [Illumina, Inc.](https://www.sectoralpha.in/us/stocks/ilmn) ILMN · leader · Evidence leans down · 71% evidence 48.4 out of 100 Growth Capital Valuation Relative
18. [OPKO Health, Inc.](https://www.sectoralpha.in/us/stocks/opk) OPK · turning · Evidence leans down · 64% evidence 48.2 out of 100 Growth Capital Valuation Relative
19. [Guardant Health, Inc.](https://www.sectoralpha.in/us/stocks/gh) GH · turning · Evidence leans down · 61% evidence 48.2 out of 100 Growth Capital Valuation Relative
20. Veracyte, Inc. this page VCYT · turning · Evidence leans down · 64% evidence 47.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue 17.3% · Profit 100% · Operating margin change 3.6 points · 62% evidence Capital efficiency 10.8/25 · ROCE 6.6% · Operating margin 15.3% · 76% evidence Valuation 9.0/20 · P/E 40.9× · PEG n/a · 15% evidence Relative strength 5.4/20 · Lead over its industry -16.1% · Lead over S&P 500 12.3% · 1 year 20.6% · 100% evidence · 2 of 12 weeks ahead Exact sum: 22.3 + 10.8 + 9 + 5.4 = 47.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 21. [NeoGenomics, Inc.](https://www.sectoralpha.in/us/stocks/neo) NEO · losing its lead · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
22. [Twist Bioscience Corporation](https://www.sectoralpha.in/us/stocks/twst) TWST · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
23. [Qiagen N.V.](https://www.sectoralpha.in/us/stocks/qgen) QGEN · breaking out · Evidence leans down · 81% evidence 45.0 out of 100 Growth Capital Valuation Relative
24. [Thermo Fisher Scientific Inc.](https://www.sectoralpha.in/us/stocks/tmo) TMO · leader · Evidence leans down · 85% evidence 44.8 out of 100 Growth Capital Valuation Relative
25. [RadNet, Inc.](https://www.sectoralpha.in/us/stocks/rdnt) RDNT · breaking out · Evidence leans down · 64% evidence 41.9 out of 100 Growth Capital Valuation Relative
26. [Waters Corporation](https://www.sectoralpha.in/us/stocks/wat) WAT · leader · Too little evidence to rank firmly · 58% evidence 39.2 out of 100 Growth Capital Valuation Relative
27. [ICON Public Limited Company](https://www.sectoralpha.in/us/stocks/iclr) ICLR · turning · Evidence leans down · 81% evidence 38.4 out of 100 Growth Capital Valuation Relative
28. [Castle Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/cstl) CSTL · breaking out · Evidence leans down · 64% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) PSNL · turning · Most evidence points down · 61% evidence 33.1 out of 100 Growth Capital Valuation Relative
30. [GeneDx Holdings Corp.](https://www.sectoralpha.in/us/stocks/wgs) WGS · quiet · Most evidence points down · 71% evidence 24.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics & Research](https://www.sectoralpha.in/us/sectors/diagnostics-research), all 30 compared on one page. ## Which companies are close to Veracyte in size? Veracyte is the 25th largest of 34 Diagnostics & Research companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: CareDx, Inc., Sotera Health Company and Adaptive Biotechnologies Corporation. Just below it: NeoGenomics, Inc., GeneDx Holdings Corp. and Personalis, Inc. ### Diagnostics & Research companies close in size

1. [CareDx, Inc.](https://www.sectoralpha.in/us/stocks/cdna) $4.6 billion
2. [Sotera Health Company](https://www.sectoralpha.in/us/stocks/shc) $4.6 billion
3. [Adaptive Biotechnologies Corporation](https://www.sectoralpha.in/us/stocks/adpt) $4.1 billion
4. Veracyte, Inc. $4 billion
5. [NeoGenomics, Inc.](https://www.sectoralpha.in/us/stocks/neo) $2.2 billion
6. [GeneDx Holdings Corp.](https://www.sectoralpha.in/us/stocks/wgs) $2 billion
7. [Personalis, Inc.](https://www.sectoralpha.in/us/stocks/psnl) $1.7 billion

[All 34 Diagnostics & Research companies, largest first](https://www.sectoralpha.in/us/sectors/diagnostics-research#all-companies)

### Companies close in size in other industries

1. [Telephone and Data Systems, Inc.](https://www.sectoralpha.in/us/stocks/tds) $3.9 billion · Telecom Services
2. [Avis Budget Group, Inc.](https://www.sectoralpha.in/us/stocks/car) $3.9 billion · Rental & Leasing Services
3. Veracyte, Inc. $3.9 billion
4. [Legence Corp.](https://www.sectoralpha.in/us/stocks/lgn) $3.9 billion · Engineering & Construction
5. [Tidewater Inc.](https://www.sectoralpha.in/us/stocks/tdw) $3.9 billion · Oil & Gas Equipment & Services

## What else do people ask about Veracyte? ### What is Veracyte's stock price today? Veracyte, Inc.'s stock price is $50.29, +39.4% over the past year. The whole company is worth $4.0 B on the market. In the last 52 weeks it traded between $30 to $60; today it is 67% of the way up from the low, 17.2% above its 200-day average (as of 3 November 2026). ### What were Veracyte's latest quarterly results? Veracyte, Inc. reported revenue of $150 M and net profit of $25.5 M for the Jun 2026 quarter. Earnings per share were $0.31. The operating margin was 15.3%, 3.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Veracyte's market cap? Veracyte, Inc.'s market capitalisation is $4.0 B at a stock price of $50.29. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Veracyte performing? Veracyte, Inc.'s share price has been rising for 7 weeks. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Veracyte's stock price go up? This page does not forecast Veracyte, Inc.'s stock price. What it shows instead: the stock price is $50.29, and it has been rising for 7 weeks. Its P/E of 36.1× is higher than 22% of its own last 2 years (as of 3 November 2026). ### Is Veracyte's profit real cash? Yes, over the last 2 years, 234% of Veracyte, Inc.'s reported profit came in as cash from operations. The latest year was lower at 205%, so the trend is worth watching. In FY25, operating cash was $136 M against reported profit of $66.4 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Veracyte in its business cycle? Veracyte, Inc.'s FY25 operating margin was 12.2%, against a 5-year range of −36.9% to 12.2%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 15.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Veracyte story? The main question: yearly earnings per share moved +164.5% while the share price moved +39.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Veracyte a stock worth studying right now? What the numbers show: Veracyte, Inc.'s results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 22% of past readings. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.